Anti-PAX9 抗体 [7C2] (ab28538)

Here is the IHC protocol I received from the laboratory that validated the antibody for this application. Please let me know if you have any questions. As I mentioned in my previous e-mail, if your protocol is similar to this one, I will be happy to discuss a replacement.

Serial sections (5 mm) were

mounted onto poly-L-lysine-coated slides, baked at

65°C overnight, deparaffinized and dehydrated according

to standard protocols. For antigen retrieval, specimens

were boiled for 4 min in a pressure cooker in

citrate buffer (10 mM, pH 6.0). Non-specific binding of

the primary antibodies was reduced by pre-incubation

of the slides with 4% dried skimmed milk in antibody

diluent. Immunostaining was performed by the streptavidin–

alkaline phosphatase technique using the Dako

ChemMate Detection Kit (DAKO, Denmark) according

to the manufacturer’s instruction, and using Fast

Red as a colour substrate. Sections were counterstained

with haematoxylin. Only distinct nuclear

staining of PAX9 was considered positive and staining

intensity was not graded in this study. Immunoreactive

cells were estimated as a percentage of the total number

of tumour cells and dysplastic cells, respectively.

PAX9 expression in dysplasias and in invasive carcinomas

was classified as reduced when the fraction of

PAX9-positive cells was smaller than 50%, and

increased when the fraction of PAX9-positive cells

was greater than 95%.

Thank you for your enquiry and your interest.

We have several antibodies against PAX9 but none of them have been tested specifically in ChIP application. Here are some which recognize mouse (murine) PAX9 and detect the native form of the protein so there is a high chance that they work in ChIP as well: ab28538, ab84830, ab85168.

I could certainly offer a Testing Discount code for your customer if she would liek to test one of them. The Terms and Conditions of this offer can be found at: https://www.abcam.com/collaborationdiscount.

Please do let me know if your customer is interested in this offer. I look forward to hearing from you soon.